肺腺癌一线治疗策略课件.pptVIP

晚期非鳞型NSCLC患者一线治疗达稳定后 是否需要维持治疗？ * * * * References: Sandler A, Yi J, Hambleton J, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).J Thorac Oncol 2008;3(Suppl. 4):S283 (Abstract 133). * * * AVAPERL: OS from inductiona Overall survival (% of patients) 100 75 50 25 0 0 3 6 9 12 15 18 21 128 127 120 103 56 20 3 0 125 123 110 96 45 17 2 0 Time (months) Bev+pem NR (34 events)Be 15.7 months (42 events) HR, 0.75 (0.47–1.20); P=0.23 Pts at risk B